β-Dystroglycan Restoration and Pathology Progression in the Dystrophic <i>mdx</i> Mouse: Outcome and Implication of a Clinically Oriented Study with a Novel Oral Dasatinib Formulation.

The 12-week treatment with dasatinib induced a clear trend toward increment of β-DG levels in either DIA ( Figure 2 B) or GC ( Figure 2 E) muscle, with the 20 mg/kg dose being more efficient in restoring β-DG protein expression, as shown by the recovery scores (10 mg/kg: 46% for DIA, 25% for GC; 20 mg/kg: 76% for DIA, 67% for GC).

also in 19,460 other papers